DR Congo expands its Ebola response as Bundibugyo cases spread across six provinces. The International Coordinating Group on Vaccine Provision authorized the release after a request from the government for doses from the global Ebola stockpile. WHO stated that 20,000 doses will be used for a Phase 3 clinical trial targeting Bundibugyo virus disease. The remaining 50,000 doses are allocated to frontline and healthcare workers following existing vaccination guidelines. The allocation was announced on August 20, and both WHO and Africa CDC have expressed support for the decision. Ervebo is licensed for use against Ebola virus outbreaks, formerly known as Zaire ebolavirus. It has not been approved specifically for Bundibugyo virus disease. Laboratory and animal studies suggest there may be some cross-protection, yet its effectiveness in humans remains uncertain. The planned clinical trial aims to evaluate how well the vaccine performs amid an ongoing outbreak and to gather data that can inform public health strategies. WHO emphasizes that recipients should be informed about the known risks, potential benefits, and current limitations of the vaccine. The outbreak now affects six provinces in Congo The initial cases appeared in the Mongbwalu health zone within Ituri Province, with confirmation from Congolese authorities in May. Since then, cases have spread into North Kivu, South Kivu, Haut-Uele, Tshopo, and Bas-Uele. As of August 12, WHO had documented 4,665 cases and 2,184